Cariprazine augmentation in treatment-resistant depression: A case-series of patients failing previous atypical antipsychotic augmentation

This case-series documents ten patients with treatment-resistant unipolar depression who had failed conventional antidepressant monotherapy and initial augmentation with standard atypical antipsychotics (aripiprazole, risperidone, or brexpiprazole). The study explores switching to cariprazine as a second-line augmentation strategy, with seven of ten patients showing clinical improvement.